# Study on the Sex-specific, Lipid- and Lipoprotein-lowering Effects of Berberine

Study · id `cardio:ct-nct06782646` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT06782646](<https://clinicaltrials.gov/study/NCT06782646>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT06782646

Browse, organ or system: Metabolism  
Browse, condition area: Risk and prevention; Diabetes and metabolic disease  

## In plain language

A phase 2/3 trial registered on ClinicalTrials.gov. The registry status is enrolling by invitation. It plans to enroll 100 participants.

## Technical summary

Registry record NCT06782646. Randomized; double masking; primary purpose prevention. Start 2024-08-01 (actual); primary completion 2025-12 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; double masking; primary purpose prevention
- Phase: Phase 2/3
- Enrolled: 100 participants (planned count; ClinicalTrials.gov record NCT06782646, source copy `cardio:ctgov-nct06782646-2025-01-20`, retrieved 2026-10-31)
- Started: 2024-08-01 (actual) (ClinicalTrials.gov record NCT06782646, source copy `cardio:ctgov-nct06782646-2025-01-20`, retrieved 2026-10-31)
- Primary completion: 2025-12 (anticipated) (ClinicalTrials.gov record NCT06782646, source copy `cardio:ctgov-nct06782646-2025-01-20`, retrieved 2026-10-31)
- Completion: 2026-03 (anticipated) (ClinicalTrials.gov record NCT06782646, source copy `cardio:ctgov-nct06782646-2025-01-20`, retrieved 2026-10-31)
- Countries: Hong Kong SAR China (ClinicalTrials.gov record NCT06782646, source copy `cardio:ctgov-nct06782646-2025-01-20`, retrieved 2026-10-31)
- Care setting: Not reported
- Registry status: "ENROLLING\_BY\_INVITATION" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct06782646-2025-01-20`, retrieved 2026-10-31)

## The registry's words

- Brief title: Study on the Sex-specific, Lipid- and Lipoprotein-lowering Effects of Berberine
- Condition: Hyperlipidemia
- Intervention (Drug): Berberine
- Intervention (Drug): Placebo
- Lead sponsor: The University of Hong Kong
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Dyslipidemia (`cardio:dyslipidemia`)
- Registry lists this organization as the lead sponsor: The University of Hong Kong (`cardio:org-the-university-of-hong-kong`)

## Provenance

Content hash: 14febb0ed14c22a4dc4084e06d0e450079039f35d6dcc015eb136887ebdec34b
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
